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article under the CC BY-NC-ND licenseAbstract Objective: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of
renal cell carcinoma (RCC) and is characterized by biallelic inactivation of the von Hippel-Lin-
dau (VHL) tumor suppressor gene. One effect of VHL inactivation is hypoxia inducible factor
alpha (HIFa)-independent constitutive activation of nuclear factor kappa B (NF-kB) and
c-jun N-terminal kinase (JNK). Both NF-kB and JNK drive ccRCC growth and epithelial to
mesenchymal transition (EMT). The purpose of this study was to determine the biochemical ef-
fects of pomegranate juice extracts (PE) on RCC cell lines.
Methods: The pre-clinical effects of PE on NF-kB, JNK, and the EMT phenotype were assayed,
including its effect on proliferation, anchorage-independent growth, and invasion of pVHL-
deficient RCCs.
Results: PE inhibits the NF-kB and JNK pathways and consequently inhibits the EMT phenotype
of pVHL-deficient ccRCCs. The effects of PE are concentration-dependent and affect not only
biochemical markers of EMT (i.e., cadherin expression) but also functional manifestations of
EMT, such as invasion. These effects are manifested within days of exposure to PE when diluted
2000-fold. Highly dilute concentrations of PE (106 dilution), which do not impact these path-
ways in the short term, were found to have NF-kB and JNK inhibitory effects and ability to
reverse the EMT phenotype following prolonged exposure.
Conclusion: These findings suggest that PE may mediate inhibition growth of pVHL-deficient
ccRCCs and raises the possibility of its use as a dietary adjunct to managing patients withet.ucla.edu (A.J. Pantuck), mrettig@mednet.ucla.edu (M.B. Rettig).
f Chinese Urological Association and SMMU.
.04.009
sian Journal of Urology. Production and hosting by Elsevier (Singapore) Pte Ltd. This is an open access
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Pomegranate inhibits ccRCCs 39active surveillance for small, localized, incidentally identified renal tumors so as to avoid more
invasive procedures such as nephrectomy.
ª 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Almost 65,000 new cases of kidney cancer are expected in
the United States in 2014, of which 90% are renal cell car-
cinomas (RCC) [1]. RCCs consist of several subtypes, the
most common of which is clear cell RCC (ccRCC), ac-
counting for 80%e85% of all renal epithelial malignancies
[1,2]. The genetic hallmark of both hereditary and sporadic
forms of ccRCC is biallelic inactivation of the von Hippel-
Lindau (VHL) tumor suppressor gene, the protein product of
which, pVHL, encodes a component of an E3 ubiquitin
ligase, the most well characterized target of which is
hypoxia inducible factor alpha (HIFa). In the context of
biallelic VHL gene loss, mutation, or inactivation that oc-
curs in upwards of 90% of sporadic ccRCCs, HIFa accumu-
lates and induces a transcriptional program, including
upregulation of cell cycle proteins (cyclin D, cyclin G2),
angiogenesis factors (VEGF), and growth factors (TGFa),
that drives ccRCC oncogenesis [3,4].
Unfortunately, our ability to exploit the pVHL-HIFa
interaction for therapeutic benefit of patients is hampered
by the fact that efficient and selective restoration of VHL
gene expression in tumor cells of actual patients is not
achievable with current gene therapy technologies, and
transcription factors such as HIFa are not readily amenable
to drug development. Moreover, small molecule therapies
that have come to the clinic over the last several years,
including the tyrosine kinase inhibitors and rapamycin an-
alogs that target select downstream targets of HIFa, have
relatively modest impact on overall survival, which is not
unexpected given that the HIFa-induced gene expression
profile dozens of genes, many of which can drive tumor
growth but are not inhibited by the aforementioned drug
classes. As such, HIFa-independent effects of pVHL have
been investigated and identified, and may represent drug-
gable targets for therapeutic intervention. Nuclear factor
kappa B (NF-kB) is constitutively activated in ccRCC patient
specimens and drives pVHL-deficient ccRCC growth and EMT
[5e9]. Recently, we have shown that the c-jun N-terminal
kinase (JNK)/activator protein 1 (AP1) pathway is consti-
tutively activated in pVHL-deficient RCCs in a HIFa-inde-
pendent fashion, and can also promote EMT and
tumorigenesis of ccRCCs [10].
Pomegranate extract (PE) has been shown to inhibit
NF-kB in normal human cells, including chondrocytes,
epidermal keratinocytes, and vascular endothelial cells
[11e13]. We have also shown that PE blocks NF-kB activity
in prostate cancer models both in vitro and in vivo [14].
Inhibition of JNK by PE in immune cells has been demon-
strated as well [15]. PE also manifests JNK modulatory ef-
fects in prostate cancer [16]. Given the role of the NF-kB
and JNK pathways in the EMT and tumorigenesis of ccRCCand the potential of PE to inhibit these pathways, we
investigated the ability of PE to inhibit constitutive NF-kB
and JNK activity and EMT in ccRCC models.
2. Materials and methods
2.1. Reagents
PE is a standardized extract (POMX, provided by POM
Wonderful, Inc., Los Angeles, CA, USA) of pomegranate
fruit grown in California, USA (Punica granatum L.,
Wonderful variety, Paramount Farms, Lost Hills, CA, USA).
PE is made from fruit skins standardized to ellagitannins
(ETs), as punicalagins (37%e40%), and free ellagic acid
(3.4%), as determined by high performance liquid chroma-
tography (HPLC) using previously described methods [17].
1000 mg of POMX powder includes up to 600 mg of poly-
phenol from extract, which delivers pomegranate poly-
phenols in an amount equivalent to about 8 oz of
pomegranate juice. The original PE liquid represents the
“1” dilution. Further dilutions were made in culture me-
dium to obtain the final concentrations employed for all
experiments. PE dilutions that were employed for most
experiments (48 h) were generally between 4  104 and
5  102. The IKKb (IKK inhibitor IV) was purchased from
Calbiochem (Gibbstown, NJ, USA; catalog 401480).
2.2. Cell lines
The RCC cell lines, ACHN and SN12C, which endogenously
express wild-type pVHL, were transduced with a lentivirus
that encodes VHL-specific shRNA or a scrambled control,
and were a kind gift of Dr. George Thomas (Oregon Health
Sciences University). These cell lines and the VHL shRNA
sequences have been previously described [18].
2.3. Transient transfections and reporter gene
assays
Cells were plated at 105 cells/well in 24-well plates the day
prior to transfection. NF-kB or AP1 driven reporter con-
structs (pkB-luc and pAP1-luc, BD Sciences, Clontech,
Mountain View, CA, USA; 1 mg per well), which express
Firefly luciferase, were co-transfected with the pRL-SV40
plasmid (Promega, Madison, WI, USA; 1 ng/well), the
latter to normalize for transfection efficiency. The plasmids
were transfected with Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s in-
structions. Protein was extracted 48 h after transfection,
and firefly and Renilla luciferase were measured on a
TD20/20 tube luminometer using a Dual Luciferase Assay kit
40 J. An et al.(Promega, Madison, WI, USA) according to the manufac-
turer’s instructions.
2.4. Electrophoretic mobility shift assays (EMSAs)
Wild-type and mutant kB and AP1 double-stranded oligo-
nucleotide probes were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Fifteen mg of nuclear
protein were combined with end-labeled, double-stranded
oligonucleotide probe, 1 mg of poly-dIdC (Amersham Phar-
macia Biotech, Piscataway, NJ, USA), 1 mg of BSA, and
5 mmol/L spermidine in a final reaction volume of 20 mL for
20 min at room temperature. The DNA protein complex was
run on a 4% non-denaturing polyacrylamide gel with 0.4
TBE running buffer prior to subsequent autoradiography.
Cold-competition experiments were performed with a 100-
fold molar excess of cold wild-type or cold mutant kB or
AP1 oligonucleotides. For supershift assays, nuclear protein
was pre-incubated with specific or control antibodies (6 mg;
purchased from Santa Cruz) for 20 min at room tempera-
ture. An identical strategy was employed for EMSAs with
Oct-1 probes as a specificity control for the effects of PEs.
2.5. Cell growth assay
Cells were seeded in 96-well plates at 1.5  104 cells per
well in 100 mL of culture medium. Cell viability was
assessed by the MTT (3,[4,5-dimethylthiazol-2-yl-] diphe-
nyltatrazolium bromide) assay. Twenty-five mL of MTT
(5 mg/mL) was added to each well for 3 h at 37 C. Sub-
sequently, 100 mL of 10% sodium dodecyl sulfate/0.01
mol/L HCl was added overnight at 37 C. Absorbance was
measured at 570 nm on a microplate reader. All experi-
ments were performed in quadruplicate.
2.6. In vitro kinase assay
An in vitro kinase assay kit (Cell Signaling Technology,
Danvers, MA, USA) was performed to measure the activity
of JNK according to the manufacturer’s instructions. An
IKKb in vitro kinase assay was modified as described [19].
Briefly, 250 mg of whole cell lysates was immunoprecipi-
tated with an anti-IKKb antibody (1:50) and then mixed
with 1 mL recombinant GST-IkB (Cell Signalling Technology)
in kinase buffer with 5 mCi of g-32P-ATP for 30 min at 30 C.
The reaction was analyzed on a Tris-Glycine gel and sub-
jected to autoradiography.
2.7. Matrigel invasion assay
The matrigel invasion assay was performed according to the
manufacturer’s instructions (BD Biosciences, San Diego, CA,
USA). Briefly, 2.5  104 cells in 0.5 mL of medium con-
taining 1% fetal bovine serum (FBS) were to the transwell
insert, which was seated in 750 mL of complete medium
(10% FBS) with or without the IKKb inhibitor (10 mmol/L).
After an overnight (12 h) incubation at 37 C in a 5% CO2
humidified atmosphere, non-invading cells were mechani-
cally removed. Cells that had migrated through the matri-
gel were stained with the Diff-Quick staining kit (Dad
Behring, Inc., Newark, DE, USA) according to themanufacturer’s instructions. Cells were counted in five
representative microscopic fields (200 magnification) and
photographed.
2.8. Western blotting
Western blotting was performed as previously described
[19,20].
2.9. Anchorage-independent growth assay
This assay was performed as described by us [19].3. Results
3.1. PE inhibits NF-kB and JNK activity in RCC cells
NF-kB activation that is driven by VHL loss induces
expression of transcription factors such as Twist and Slug
that suppress E-cadherin expression, increase N-cadherin
expression, and heighten cellular invasiveness and
anchorage-independent growth. We have previously shown
that the SN12C-VHLlow and ACHN-VHLlow cell lines, which
are isogenic partners of SN12C and ACHN stably transduced
with VHL-specific shRNA, acquire an EMT phenotype
consistent with their constitutive activation of NF-kB
[18,20]. NF-kB activation is mediated through the IKK
complex, which phosphorylates the NF-kB inhibitor, IkB,
thereby marking it for ubiquitination and proteasome-
dependent degradation. We and others have previously
described that pVHL-deficient RCCs manifest increased NF-
kB activity compared to isogenic cells that express wild-
type pVHL [8,21]. Given the previously described NF-kB
inhibitory effects of PE in other model systems [14], we
investigated the effects of PE on constitutive NF-kB activity
in pVHL-deficient RCC cells. Indeed, IKK activity as
measured by in vitro kinase assays was inhibited in a con-
centration dependent fashion (Fig. 1A). The phosphoryla-
tion of IkB, the substrate of the IKK complex, was also
reduced as demonstrated by Western blotting (Fig. 1B).
Upon degradation of IkB, NF-kB transcription factors,
which reside in the cytoplasm in the quiescent state, are
disinhibited and translocate to the nucleus, where they
bind to kB DNA binding sites in the regulatory regions of
target genes. Inhibition of NF-kB binding to consensus kB
response elements by PE was demonstrated by electro-
phoretic mobility shift assays (EMSAs) as shown in Fig. 1C.
Lastly, the functional effects of PE on the NF-kB pathway
were illustrated by the concentration-dependent inhibition
of NF-kB driven reporter gene activity (Fig. 1D).
We recently reported that pVHL-deficiency was causally
linked to constitutive activation of JNK, which in turn phos-
phorylates c-jun, leading tosubsequentheterodimerizationof
phospho-c-jun to c-fos to form transcriptionally competent
AP1 complexes [10]. AP1 induces expression of Twist, a key
mediator of EMT that suppresses E-cadherin and induces N-
cadherin expression [10]. The net effect of AP1 activation is
heightened growth and tumorigenesis of pVHL-deficient
ccRCCs [10]. In light of these AP1-mediated effects, we
determined whether PE could inhibit JNK activity analogously
Figure 1 PE inhibits constitutive NF-kB activity in pVHL-deficient RCCs. (A) IKKb in vitro kinase assays. After overnight exposure
of pVHL deficient RCCs (ACHN-VHLlow and SN12C-VHLlow) to the indicated dilutions of PE, IKKb was immunoprecipitated and
phosphorylation of a recombinant substrate, GST-IkB, was assessed by immunoblotting. The dilutions of PE are shown, with “V”
indicating vehicle control. (B) Western blots for phosphorylated IkB after overnight exposure to the indicated dilutions of PE. (C)
EMSAs for NF-kB after overnight exposure to PE. Cold competition experiments illustrate the specificity of the gel shifted bands: m,
mutant kB oligonucleotide probe; wt, wild-type kB oligonucleotide probe. (D) NF-kB driven reporter assays after 48 h of PE
exposure. Results are means  SD of triplicate experiments. Results were normalized to that of vehicle treated cells.
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tional activity of JNK in a concentration-dependent fashion as
measured by in vitro kinase assays (Fig. 2A). Moreover, phos-
phorylation of c-jun at serine 73, a phosphorylation site ofFigure 2 PE inhibits constitutive JNK activity in pVHL-deficient R
PE, total JNK was immunoprecipitated, and JNK activity was mea
noblotting. (B) Western blots for phosphorylated c-jun and total
assays performed 48 h of PE exposure. Results are means  SD of tri
treated cells.JNK, was reduced by PE in a similar manner (Fig. 2B). As
further evidence of JNK blockade, a concentrationdependent
inhibition of AP1-driven reporter gene expression by PE was
demonstrated (Fig. 2C).CCs. (A) JNK in vitro kinase assays. After overnight exposure to
sured by phosphorylation of recombinant GST-c-jun by immu-
c-jun after overnight exposure to PE. (C) AP1 driven reporter
plicate experiments. Results were normalized to that of vehicle
Figure 3 Effects of PE on in vitro growth on plastic and anchorage-independent growth in soft agar. (A) ACHN-VHLlow or SN12C-
VHLlow cells were treated with the indicated dilutions of PE for 120 h. Total cell number was measured in MTT assays. Results are
means  SD of quadruplicate experiments. (B) Anchorage-independent growth was assessed by growth of ACHN-VHLlow or SN12C-
VHLlow in soft agar with the indicated dilutions of PE for 14 days. Results are means  SD of number of colonies per microscopic field
(final magnification, 200).
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RCCs
Given the NF-kB and JNK inhibitory properties of PE and the
role of these signaling pathways in promoting proliferation,
growth and EMT, we assessed the functional impact of PE on
pVHL-deficient RCCs. PE inhibited the in vitro growth of
both SN12C-VHLlow and ACHN-VHLlow cells in a concentra-
tion dependent manner as measured in MTT assays over
120 h (Fig. 3A). Next, we tested the effect of PE on
anchorage-independent growth. PE reduced not only the
size of individual colonies (not shown), an indicator of
proliferation, but also the total number of colonies formed
in soft agar (Fig. 3B), an in vitro marker of metastatic po-
tential [22].
At baseline, pVHL-deficient ACHN and SN12C cells exhibit
high N-cadherin and low E-cadherin expression character-
istic of a mesenchymal phenotype (Fig. 4A). Upon exposure
to PE, cells underwent a “cadherin switch” in which the
heightened N-cadherin/low E-cadherin pattern reverted to
a high E-cadherin/low N-cadherin pattern typified by
epithelial cells (Fig. 4A). Importantly, PE also inhibited
invasiveness of pVHL-deficient cells in a matrigel invasion
chamber in a concentration-dependent manner, a hallmark
of EMT (Fig. 4B and C); cell numbers were not significantly
affected in pVHL-deficient cells during the overnight time
course required for the matrigel invasion assay, indicating
that the effects of PE on proliferation did not influence the
results of the invasion assays. Taken together, our results
indicate that PE inhibits growth and EMT of pVHL-deficient
cells by inducing a reversion of the mesenchymal pheno-
type that is characteristic of pVHL-deficient RCCs to a
phenotype that more closely resembles that of epithelial
cells. These findings are consistent with previous reports
demonstrating the plasticity of EMT in ccRCCs, which can
undergo a reversion to an epithelial phenotype (i.e., a
mesenchymal to epithelial transition or MET) upon inhibition
of the JNK or NF-kB pathways [10,20].3.3. Prolonged exposure to low concentrations of
PE inhibits constitutive NF-kB and JNK activation
and induces a “cadherin switch”
In the aforementioned experiments, we exposed SN12C-
VHLlow and ACHN-VHLlow to concentrations of PE that were
sufficient to inhibit molecular targets of interest over
24e48 h. In the following experiments, we determined
whether substantially more dilute concentrations of PE,
which perhaps may not exhibit NF-kB and/or JNK inhibitory
activity over relatively short time periods, may in fact
effectively inhibit these signaling pathways when cells are
exposed to PE for prolonged durations (i.e. weeks).
We used PE at a 106 dilution of the stock solution and
tested the effects of dilute PE on NF-kB and JNK activity as
well as the expression of E-cadherin and N-cadherin. Ef-
fects of dilute PE on JNK and NF-kB were not observed until
approximately 10 days of exposure; continued treatment
led to further inhibition with robust blockade of both IKK
and JNK activity observed after 24 days (Fig. 5). The
reversal of cadherin expression manifested different ki-
netics for N-cadherin and E-cadherin. N-cadherin expres-
sion remained largely unaffected until Day 14, after which
time its expression was reduced through Day 24 (Fig. 5).
Conversely, E-cadherin expression was induced at earlier
time points (i.e. Day 2) and reached maximal expression
levels by Day 5 (ACHN) or Day 10 (SN12C). The relatively
early change to E-cadherin expression in the absence of
demonstrable inhibition of NF-kB or JNK suggests that
biochemical signaling pathways independent of NF-kB and
JNK may be operative in regulating E-cadherin expression in
response to PE. This phenomenon does not exclude the role
of NF-kB and JNK perhaps at later time points, especially
given the abundance of previous reports causally linking
these pathways to EMT and cadherin expression in pVHL-
deficient models. Nonetheless, prolonged exposure to
extremely dilute concentrations of PE led to a time
dependent inhibition of constitutive NF-kB and JNK activity
Figure 4 Inhibition of EMT phenotype by PE. (A) PE induces a “cadherin switch”. Western blots for the indicated proteins after
48 h of exposure to the indicated dilutions of PE. (B) PE inhibits invasion of pVHL-deficient RCCs. Invasion was measured in a
Matrigel invasion assay after overnight exposure to the indicated dilutions of PE. PE did not affect the overall number of cells during
overnight exposure, so that the invasion results were not influenced by differences in cell number. Results are the means  SD of
the number of cells counted per microscopic field (final magnification, 200). Results were normalized to that of vehicle treated
cells. (C) Images of cell invasion assays.
Pomegranate inhibits ccRCCs 43and induced a “cadherin switch” characterized by
increasing E-cadherin and decreasing N-cadherin expression
consistent with reversion to an epithelial phenotype.
4. Discussion
Approximately 65,000 cases of and 13,500 deaths attribut-
able to kidney cancer are expected in the United States in
2012 [2]. Most kidney cancers are RCCs, and deaths areFigure 5 Highly diluted PE inhibits NF-kB and JNK activity and in
ACHN-VHLlow and (B) SN12C-VHLlow were exposed to highly dilute c
exposed to dilute PE for the indicated number of days, and IKKb
(middle panels), and Western blots for cadherins (bottom panels)caused by metastatic disease and its complications. Novel
treatments, which include rapamycin analogs (e.g., ever-
olimus and temsirolimus) and tyrosine kinase inhibitors
(e.g., pazopanib, sunitinib, etc.) that target various plasma
membrane (e.g., VEGFR) and intracellular kinases (e.g.,
Raf), are modestly and only transiently effective and do not
eradicate the disease [23]. Thus, despite the advent of
several agents to treat metastatic RCC, the disease remains
essentially incurable.duces a “cadherin switch” over prolonged exposure times. (A)
oncentrations of PE (diluted 106 in vehicle). Cells were then
in vitro kinase assays (top panels), JNK in vitro kinase assays
were performed.
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activated in tumor cells as a result of “driver” genetic le-
sions such as biallelic inactivation of the von Hippel-Lindau
tumor suppressor gene (VHL), can provide opportunities for
therapeutic intervention. For example, the NF-kB pathway
is constitutively activated in response to VHL loss and in-
duces RCC growth and EMT [5e9,21]. Recently, we identi-
fied JNK activation in VHL-inactivated tumors; in this
context, JNK induces EMT and heightened tumorigenesis
[10]. Thus, both NF-kB and JNK represent pathways that
appear to be primed for therapeutic intervention of ccRCC.
Here, we have shown that PE inhibits the NF-kB and JNK
pathways and consequently inhibits the EMT phenotype of
pVHL-deficient ccRCCs. The effects of PE are
concentration-dependent and affect not only biochemical
markers of EMT (i.e., cadherin expression) but also func-
tional manifestations of EMT, such as invasion. Anchorage-
independent growth was also inhibited. Whereas the
antiproliferative effects of PE may account for the
reduced colony size in anchorage-independent growth
assays, the number of colonies is not affected by prolif-
eration. Importantly, highly diluted concentrations of PE
when maintained over a prolonged duration were also able
to reverse EMT, a finding that may have clinical and
translational implications in that low dose daily ingestion
of PE may have anti-tumor effects. Additional in vivo
studies will be warranted to further pre-clinically validate
PE as a potentially active clinical approach to RCC. One
particular scenario in which clinical usage of PE in this
fashion may be particularly germane is in the management
of incidentally identified small renal tumors. The inci-
dence of RCCs has dramatically increased over the last
10e15 years, with the marked rise in incidence attribut-
able to detection of early stage but not advanced stage
tumors [24,25]. The increased usage of radiographic
studies, including CT and ultrasonography are capturing
incidental, small renal tumors. Many of these tumors have
slow growth kinetics and fairly low risk for progression to
more advanced stage [26e30]. The recognition that many
small renal tumors demonstrate low malignant potential
and that treatment may pose a greater risk than following
patients over time has led to the concept of active sur-
veillance. Initial active surveillance with delayed treat-
ment for patients who progress has become an accepted
practice in elderly patients or those with significant co-
morbidities in whom the risk of treatment is deemed
high [26e30]. It is in this setting that PE consumption may
have a clinical role in preventing the progression of small,
incidentally detected RCCs from disease progression. Such
an approach could obviate the need for invasive pro-
cedures, such as partial or radical nephrectomy or other
techniques such as cryoablation and radiofrequency
ablation. Of course, the use of PE for the long-term
management of small renal tumors would require formal
clinical investigation, but the results presented herein
along with previous reports relating NF-kB and JNK acti-
vation to RCC progression provide the pre-clinical foun-
dation for clinical trials aimed at demonstrating that PE
can effectively prevent the progression or perhaps induce
regression of small renal tumors, an increasing clinical
problem arising from the heightened use of radiographic
modalities for abdominal imaging.Conflicts of interest
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